The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Becton Dickinson to buy CareFusion for $12 bln in cash, stock

Sun, 05th Oct 2014 21:50

(Adds background, CEO comments)

By Deena Beasley

Oct 5 (Reuters) - Medical equipment supplier BectonDickinson & Co has agreed to buy CareFusion Corp, a maker of infusion pumps and other medical devices,for $12.2 billion in cash and stock, marking the latestmultibillion-dollar healthcare sector deal.

Becton said on Sunday it would pay a total of $58.00 a share- $49.00 in cash and 0.0777 of a share of Becton Dickinson - foreach share of CareFusion, representing a premium of 26 percentto the closing price on Oct. 3.

The acquisition, recommended by the boards of bothcompanies, is aimed at combining the two U.S.-based companies'complementary products for preparing, administering andmonitoring patient medications while also extending theirgeographical reach.

BD makes products to deliver and administer drugs, likedisposable needles, syringes and IV (intravenous) catheters,while CareFusion makes products to store the drugs and todeliver them, such as infusion pumps.

A combined company "could improve patient safety plus reducecosts at the same time," said Vincent Forlenza, BectonDickinson's chairman, chief executive officer and president in atelephone interview.

Cost-related healthcare reforms, including those mandatedunder President Barack Obama's Affordable Care Act, have spurredconsolidation for U.S. health systems and hospitals, the maincustomer for both Becton Dickinson and CareFusion.

"This is an industry that from a customer perspective isconsolidating," said Kieran Gallahue, CareFusion's chairman andCEO. "Healthcare systems around the globe are looking forcompanies that can bring greater scale to them - it is a way todrive down costs while improving safety at the same time."

Forlenza said Becton's geographic reach - around 60 percentof its sales are outside of the United States and 25 percent ofsales are in emerging markets - offers a strong platform forproducts from CareFusion, which currently relies on the domesticmarket for 75 percent of its revenue.

Becton said the transaction is expected to providedouble-digit earnings growth, on an adjusted basis, in the firstfull year, and will be accretive to net earnings in fiscal year2018.

The deal, subject to regulatory and CareFusion shareholderapprovals and customary closing conditions, is expected to closein the first half of next year.

At closing, the companies said Becton Dickinson shareholderswill own around 92 percent of the combined company andCareFusion shareholders will own around 8 percent.

Healthcare companies have been merging at a record pace,with year-to-date activity topping $346 billion, compared to$212 billion in the year-ago period, Thomson Reuters data showed as of September.

Recent large deals have included AbbVie Inc's planned $54 billion acquisition of Shire Plc andMedtronic Inc's planned acquisition of Covidien Plc for $43 billion. AstraZeneca Plc, meanwhile,fended off a $118 billion takeover attempt by Pfizer Inc. (Reporting By Deena Beasley; Editing by Chizu Nomiyama)

More News
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.